The DRTB-HDT Consortium Meeting 2024 took place just outside Johannesburg, South Africa, with the breathtaking African Hills Safari Lodge as its backdrop. Over two productive days, consortium members gathered to discuss key aspects of the study as it enters its final year.
Key discussions centered on recruitment progress, patient retention, and strategies for sharing findings as we move into the data analysis phase. With such an international team, the opportunity to meet in person was invaluable. A game drive on the first day provided a chance to appreciate the stunning surroundings and strengthen collaborations beyond the conference room.
The meeting concluded with a visit to the Aurum Tembisa Clinical Research Site, one of the study’s key locations in South Africa, offering firsthand insight into the important work being done on the ground.
Key takeaways from the meeting are:
- Recruitment is ending in March 2025
- The first samples from all sites are being shipped and getting ready for LJ and MGIT culture
The consortium will be working on the first of a few publications this year.
Representing the Institutul de Pneumoftiziologie “Marius Nasta” in Bucharest, Romania, are Dr. Elmira Ibraim, Dr. Dragos Baiceanu, and Dr. Traian Panciu. As the largest tertiary clinic for lung diseases in the country and home to the National TB Reference Laboratory, the institute plays a crucial role in combating tuberculosis.
With Romania’s population of 19 million and approximately 9,122 TB cases reported, the team has been making significant strides. In recent months, they have surpassed their initial enrollment targets, demonstrating their commitment to advancing TB research. Their involvement in the DRTB-HDT consortium has further strengthened their expertise in international clinical trials and spirometry testing, enhancing both patient care and scientific collaboration.
Bridging Communities and Research: Zithelo Zikalala’s Journey in TB Engagement
Ending drug-resistant TB (DR-TB) starts with the people affected by it. When communities are informed, involved, and heard, research becomes more than science, it becomes a solution that works for them. Community engagement builds trust, removes barriers to care, and ensures studies lead to real change.
Zithelo Zikalala has always placed connecting with people at the heart of his work. As the Community Engagement Manager for the DRTB-HDT study at The Aurum Institute Tembisa Clinical Research Site, he plays a role in ensuring that drug-resistant TB (DR-TB) research not only advances science but also serves the people who need it most.
Transforming Lives Through the DRTB-HDT Study
In young adulthood, this participants’ life took an unexpected turn when she was diagnosed with multidrug-resistant tuberculosis (MDR-TB). After months of persistent symptoms, she sought medical attention and was referred to Tembisa Hospital View. It was there that she became part of the DRTB-HDT Study, a groundbreaking research initiative focused on advancing the treatment of MDR-TB, with The Aurum Institute, Clinical Research Site in Tembisa.
The Impact of the DRTB-HDT Study
The DRTB-HDT Study is striving to end drug-resistant tuberculosis (DRTB) by providing participants with comprehensive care and contributing to global advancements in treatment. One of the research participants, from the Gauteng region, shares her experience in this transformative initiative.